drugset / Trial / NCT00320541
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer
Timeline
- Start
- 2006-05
- Primary completion
- 2009-04
- Completion
- 2012-08
Outcome
Missed primary endpoint
registry p = 0.117; Fisher Exact; note: Statistical significance at 0.05 level was required. NCT00320541 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1500 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 90 mg/m2 | Intravenous |